Statin Warning For Coenzyme Deficiency Sought In FDA Citizen Petition
This article was originally published in The Pink Sheet Daily
Executive Summary
Citizen petition supplement pushes for a warning, similar to that carried on statin drugs in Canada, about the risk of CoQ10 depletion. Petitioner seeks a statement that CoQ10 deficiency “is associated with impairment of myocardial function, with liver dysfunction, and with myopathies.”
You may also be interested in...
Canada Updates Statin Labeling On Muscle Toxicity, Adds Predisposing Factors
Health Canada universalizes statin safety labeling; warning adds list of predisposing factors for rhabdomyolysis and myopathy. Lists are similar to U.S. labeling, but not identical.
Canada Updates Statin Labeling On Muscle Toxicity, Adds Predisposing Factors
Health Canada universalizes statin safety labeling; warning adds list of predisposing factors for rhabdomyolysis and myopathy. Lists are similar to U.S. labeling, but not identical.
Statin Drug Warning On Coenzyme Q10 Levels Sought In Lawsuit Against FDA
Lawsuit follows agency's denial of a citizen petition requesting a warning about coenzyme Q10-depleting effects of cholesterol-lowering drugs. FDA says there is "no reasonable evidence" for concluding that statin-induced decreases in CoQ10 levels are associated with adverse events.